GlassScriptPhysician profile
Peggy A Byun
NPI 1720080674
$1,439.39
in general payments reported to CMS, 2019-2025
25 companies · $270 in 2025
The $270 reported for 2025 was more than what 82% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $526 · 2020: $117 · 2021: $11.20 · 2022: $17.11 · 2023: $132 · 2024: $366 · 2025: $270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $768.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $768.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $198.77 | 2019-2025 | |
| Cranial Technologies, INC | $171.72 | 2019-2025 | Doc Band |
| Glaxosmithkline, LLC. | $152.55 | 2019-2025 | Bexsero, Rotarix, Penmenvy |
| Merck Sharp & Dohme LLC | $123.83 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaqta |
| Ironshore Pharmaceuticals INC. | $113.96 | 2019-2024 | Jornay Pm |
| Neos Therapeutics, LP | $61.72 | 2019-2025 | Cotempla Xr-Odt |
| Kaleo, INC. | $60.69 | 2019-2024 | Auvi-Q |
| Tris Pharma INC | $59.77 | 2019-2020 | |
| Genentech USA, INC. | $59.36 | 2019-2020 | |
| Ars Pharmaceuticals Operations, INC. | $37.13 | 2025 | Neffy |
| Adlon Therapeutics L.P. | $36.47 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $35.66 | 2019 | |
| Shire North American Group INC | $33.33 | 2019 | |
| Supernus Pharmaceuticals, INC. | $33.13 | 2022-2024 | Qelbree |
| Novo Nordisk INC | $31.30 | 2023-2024 | Wegovy |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $28.34 | 2019-2023 | |
| Alk-Abello, INC | $27.05 | 2025 | Neffy |
| Biogen, INC. | $25.16 | 2024 | Spinraza |
| Avion Pharmaceuticals | $24.73 | 2023 | Methylphenidate Hydrochloride |
| Sanofi-Aventis U.S. LLC | $23.31 | 2024 | |
| Hologic Sales and Service, LLC | $21.08 | 2025 | Aptima |
| Organon LLC | $20.88 | 2025 | |
| Ironwood Pharmaceuticals, INC | $20.81 | 2024 | |
| Phadia US INC. | $19.49 | 2019 | |
| Verrica Pharmaceuticals INC. | $19.15 | 2024 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peggy Byun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.